Can I Take Ashwagandha with Oral Micronized Progesterone (Prometrium)?

How Oral Micronized Progesterone Works

Oral micronized progesterone is body-identical progesterone suspended in peanut oil and enclosed in a soft gelatin capsule. The FDA approved Prometrium in 1998 for endometrial protection in postmenopausal women receiving estrogen, and for secondary amenorrhea. [1]

Absorption and Metabolism

OMP is absorbed via the lymphatic system before entering portal circulation, which partially bypasses first-pass hepatic metabolism compared with synthetic progestins. Peak serum progesterone occurs at roughly 2 to 3 hours post-dose. The Endocrine Society's 2022 menopause guideline notes that OMP produces serum progesterone levels sufficient for endometrial protection at 100 to 200 mg nightly. [2]

CYP3A4 handles the majority of progesterone biotransformation into 5-alpha- and 5-beta-reduced metabolites, including allopregnanolone. [3] Any agent that inhibits or induces CYP3A4 has at least theoretical potential to change OMP exposure.

Why Body-Identical Matters for Interaction Risk

Synthetic progestins such as medroxyprogesterone acetate bind glucocorticoid and androgen receptors broadly. OMP is more receptor-selective, binding primarily the progesterone receptor with minimal glucocorticoid or androgenic off-target activity. [4] That selectivity narrows, but does not eliminate, the interaction surface with ashwagandha.

What Ashwagandha Does Pharmacologically

Ashwagandha is an adaptogenic herb used in Ayurvedic medicine for over 3,000 years. Its primary bioactive compounds are withanolides, alkaloids, and saponins. Clinically relevant effects documented in human trials include cortisol reduction, thyroid stimulation, and modest testosterone elevation.

Cortisol and HPA-Axis Effects

A randomized, double-blind trial published in the Indian Journal of Psychological Medicine (N=64) found that ashwagandha 300 mg KSM-66 extract twice daily reduced serum cortisol by 27.9% versus 7.9% placebo over 60 days (P<0.001). [5] A separate 8-week RCT (N=60) using 240 mg of a standardized root extract reported a 23% reduction in morning cortisol. [6]

Cortisol and progesterone share the same biosynthetic precursor: pregnenolone. Chronically elevated cortisol can divert pregnenolone away from progesterone synthesis, a pattern sometimes called "pregnenolone steal." Lowering cortisol with ashwagandha may therefore support endogenous progesterone production in premenopausal women, but this effect is largely irrelevant when exogenous OMP is the therapeutic source.

Thyroid Hormone Effects

A peer-reviewed study in the Journal of Alternative and Complementary Medicine (N=50) found that ashwagandha 600 mg/day for 8 weeks significantly increased serum T3 (by 41.5%) and T4 (by 19.6%) in adults with subclinical hypothyroidism. [7] Thyroid hormones accelerate hepatic CYP enzyme activity and increase sex hormone-binding globulin (SHBG). [8] Elevated SHBG binds progesterone and reduces free-fraction availability, meaning thyroid stimulation by ashwagandha could theoretically reduce the effective free progesterone concentration.

Androgen and Testosterone Effects

A 16-week RCT in the American Journal of Men's Health (N=57) showed that ashwagandha 675 mg/day raised serum testosterone by 14.7% in healthy adult males. [9] Withanolides exhibit partial agonist activity at androgen receptors. [10] In women, supraphysiologic androgens can down-regulate progesterone receptor expression in endometrial tissue, though the modest testosterone increases from typical ashwagandha doses are unlikely to reach that threshold.

CYP3A4 Inhibition Potential

In vitro data show that withanolide A inhibits CYP3A4 activity, but the concentration required (<20 µM) is substantially higher than plasma levels achieved with standard oral doses of 300 to 600 mg/day. [11] A 2020 review in Phytomedicine concluded that clinically meaningful CYP3A4 inhibition from ashwagandha at normal supplement doses is unlikely, though confirmatory human pharmacokinetic studies are still sparse. [12] Because OMP relies on CYP3A4 for clearance, this remains a watch-item, not a contraindication.

The Pharmacodynamic Interaction: What Actually Matters

No clinical trial has directly studied the combination of OMP and ashwagandha. The interaction profile below is built from mechanism-based reasoning and individual compound data.

Cortisol Pathway: Net Effect Likely Neutral to Favorable

When cortisol falls, the progesterone receptor becomes more sensitive to progesterone signaling in some tissue models. [13] For a postmenopausal woman taking OMP for endometrial protection, this means ashwagandha-mediated cortisol reduction is unlikely to reduce therapeutic efficacy. If anything, lower glucocorticoid receptor competition may slightly enhance progesterone receptor signaling. The clinical magnitude of this effect is unquantified.

Thyroid Pathway: The More Relevant Concern

Ashwagandha-induced thyroid stimulation is the mechanism that warrants monitoring. A rise in free T3 and T4 increases hepatic SHBG synthesis and accelerates CYP3A4-mediated progesterone catabolism. [8] Women with pre-existing subclinical hypothyroidism who start ashwagandha may see TSH drop and thyroid hormones rise noticeably, shifting progesterone metabolism faster than expected. A baseline TSH before starting ashwagandha is practical clinical care for any woman on OMP.

The HealthRX clinical team applies a three-tier monitoring framework when evaluating adaptogen-progestogen combinations:

Tier 1 (low risk, monitoring optional): No thyroid disorder, normal cortisol, OMP dose stable for >3 months. Ashwagandha at 300 mg/day is generally acceptable with periodic clinical review.

Tier 2 (moderate risk, monitoring recommended): Subclinical hypothyroidism, adrenal fatigue history, or OMP dose recently adjusted. Check TSH, free T4, morning cortisol, and serum progesterone at baseline and 6 to 8 weeks after adding ashwagandha.

Tier 3 (higher risk, prescriber discussion required before starting): Overt thyroid disease (treated or untreated), concomitant use of thyroid medications (levothyroxine), or concurrent use of other CYP3A4 modulators. The combination is not contraindicated, but the prescriber needs to adjust monitoring intervals.

Androgenic Pathway: Minimal Clinical Concern at Standard Doses

The 14.7% testosterone increase reported in males [9] translates to a smaller absolute rise in women given lower baseline testosterone levels. Typical female testosterone sits at 15 to 70 ng/dL. A 14.7% increase from the midrange (~40 ng/dL) yields roughly 46 ng/dL, which remains well within the normal female reference range and far below the threshold at which androgen excess suppresses endometrial progesterone receptor expression. This pathway is worth noting but is not a reason to avoid the combination.

What the Guidelines Say

No major guideline (NAMS, Endocrine Society, ACOG) has published a specific recommendation on ashwagandha co-administration with OMP, because the combination has not been formally studied in a clinical trial. The 2022 NAMS Menopause Practice: A Clinician's Guide states that herbal and dietary supplements should be reviewed at every visit for women on hormone therapy, and that patient-reported supplement use is frequently incomplete. [14]

The Endocrine Society's 2015 clinical practice guideline on postmenopausal hormone therapy advises that any agent affecting thyroid function or hepatic metabolism should be disclosed to the prescribing clinician. [2]

The FDA's current Prometrium prescribing information lists CYP3A4 inducers and inhibitors as drugs that may alter OMP exposure, but does not specifically list botanical supplements. [1] That omission reflects a data gap, not confirmed safety.

Practical Dosing and Timing Guidance

Standard OMP Dosing Context

OMP is typically prescribed at 100 mg nightly (continuous regimens) or 200 mg nightly for 12 days per cycle (cyclic regimens) for endometrial protection. [1] For secondary amenorrhea, the dose is 400 mg at bedtime for 10 days. Taking OMP at bedtime is standard practice because its allopregnanolone metabolites produce sedation.

Ashwagandha Dosing in Women

Clinically studied doses in women range from 240 mg/day (standardized root extract) to 600 mg/day (KSM-66 or Sensoril extract). [5] [6] A 2021 study in Medicine specifically in women (N=50) found that KSM-66 at 300 mg twice daily over 8 weeks improved sexual function scores and reduced distress without significant adverse events. [15] Doses above 600 mg/day have not been well-characterized for interactions.

Timing Separation

No pharmacokinetic data support a mandatory separation window. Because OMP is best taken at bedtime and ashwagandha is often taken with food in the morning or evening, the two naturally separate by several hours in most schedules. This practical separation reduces any theoretical overlap in peak plasma concentrations.

Foods and Other Supplements to Watch

OMP is taken with food or at bedtime to improve absorption and reduce GI side effects. Grapefruit juice inhibits CYP3A4 and measurably increases OMP exposure; patients on OMP should avoid grapefruit consistently. [3] If a patient is also taking St. John's Wort (a strong CYP3A4 inducer), adding ashwagandha on top compounds the interaction complexity and warrants prescriber review.

Monitoring Recommendations

Before Starting Ashwagandha on OMP

Obtain a baseline:

• Serum TSH and free T4
• Morning serum cortisol (8 AM draw)
• Serum progesterone (mid-luteal if premenopausal, trough if postmenopausal on continuous therapy)
• Total and free testosterone (if androgenic symptoms are present)

At 6 to 8 Weeks

Repeat TSH and free T4. If TSH has dropped by more than 0.5 mIU/L from baseline, flag for prescriber review, particularly in women already on levothyroxine, since ashwagandha may reduce the required levothyroxine dose. [7] Serum progesterone should be within the therapeutic range; if symptoms of progesterone insufficiency appear (breakthrough bleeding, sleep disruption, mood changes), a trough progesterone level can guide dose adjustment.

Ongoing

Annual thyroid screening is standard for women on HRT. [2] Patients combining ashwagandha should receive this check no less frequently.

Special Populations

Perimenopausal Women

Perimenopausal women may use OMP for luteal-phase support or cycle regulation. Cortisol dysregulation is common in perimenopause, and ashwagandha's HPA-axis modulation may offer additional benefit. [16] The thyroid concern still applies; TSH screening at baseline is recommended.

Women with Thyroid Disease

Women with Hashimoto's thyroiditis or treated hypothyroidism using levothyroxine alongside OMP face the most complex picture. Ashwagandha may lower TSH and require a levothyroxine dose reduction. [7] Prescriber coordination is required before starting ashwagandha in this group.

Women with Anxiety or Insomnia

OMP's sedative allopregnanolone metabolites plus ashwagandha's GABA-A-modulating withanolides may produce additive sedation. [17] One 8-week RCT (N=60) found that ashwagandha 120 mg/day improved sleep quality scores by 72% over placebo. [18] Combined sedation is generally well-tolerated and may be a therapeutic advantage for women using OMP primarily for sleep, but patients should be counseled to avoid driving or operating heavy machinery within 4 to 6 hours of taking OMP at bedtime if they add ashwagandha in the evening.

Pregnancy

OMP is used in early pregnancy for luteal-phase support in assisted reproductive technology. Ashwagandha has demonstrated abortifacient properties in animal models at high doses. [19] Until human safety data are available, ashwagandha should not be used concurrently with OMP in any pregnant or actively trying-to-conceive patient. ASRM guidelines emphasize avoiding all unvetted supplements during ART cycles. [20]

When to Contact Your Prescriber

Contact your prescriber promptly if you notice:

• Breakthrough uterine bleeding on a previously stable OMP regimen after starting ashwagandha
• Palpitations, heat intolerance, or unexplained weight loss (signs of thyroid over-stimulation)
• Excessive sedation lasting more than 2 hours after the morning ashwagandha dose
• New symptoms of androgen excess (acne, hair thinning, or clitoral sensitivity changes)

None of these are expected outcomes at standard doses, but all are actionable signals for laboratory re-evaluation rather than self-adjustment of either agent.

Summary of the Interaction Evidence Quality

The overall evidence quality for this specific combination is low, because no head-to-head clinical trial exists. Individual compound data are moderate quality for ashwagandha's cortisol and thyroid effects (multiple small RCTs, consistent direction) and high quality for OMP's pharmacokinetics (FDA-reviewed pharmacology). The theoretical interaction framework is internally consistent, but the absence of confirmatory human combination data means clinical caution is appropriate rather than prohibition. Women who are already taking both without issues and have normal thyroid and progesterone levels do not need to stop, but they should ensure their prescriber knows.